147 related articles for article (PubMed ID: 29954488)
1. Glutaryl Polyamidoamine Dendrimer for Overcoming Cisplatin-Resistance of Breast Cancer Cells.
Xu X; Li Y; Lu X; Sun Y; Luo J; Zhang Y
J Nanosci Nanotechnol; 2018 Oct; 18(10):6732-6739. PubMed ID: 29954488
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
3. para-Sulfonatocalix[4]arene and polyamidoamine dendrimer nanocomplexes as delivery vehicles for a novel platinum anticancer agent.
Pang CT; Ammit AJ; Ong YQE; Wheate NJ
J Inorg Biochem; 2017 Nov; 176():1-7. PubMed ID: 28810174
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of Anticancer Action of Novel Imidazole Platinum(II) Complex Conjugated with G2 PAMAM-OH Dendrimer in Breast Cancer Cells.
Czarnomysy R; Muszyńska A; Rok J; Rzepka Z; Bielawski K
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070401
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin.
Kirkpatrick GJ; Plumb JA; Sutcliffe OB; Flint DJ; Wheate NJ
J Inorg Biochem; 2011 Sep; 105(9):1115-22. PubMed ID: 21704583
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
[TBL] [Abstract][Full Text] [Related]
7. Nano-carrier Polyamidoamine Dendrimer G4 Induces Mitochondrialdependent Apoptosis in Human Multidrug-resistant Breast Cancer Cells through G0/G1 Phase Arrest.
Zhang J; Wu Z; Zhan S; Li M; Wang Y; Xu H; Ding B; Gao J
Curr Pharm Biotechnol; 2023; 24(4):589-598. PubMed ID: 36043717
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer.
Fu F; Wu Y; Zhu J; Wen S; Shen M; Shi X
ACS Appl Mater Interfaces; 2014 Sep; 6(18):16416-25. PubMed ID: 25185074
[TBL] [Abstract][Full Text] [Related]
9. The cellular uptake mechanism, intracellular transportation, and exocytosis of polyamidoamine dendrimers in multidrug-resistant breast cancer cells.
Zhang J; Liu D; Zhang M; Sun Y; Zhang X; Guan G; Zhao X; Qiao M; Chen D; Hu H
Int J Nanomedicine; 2016; 11():3677-90. PubMed ID: 27536106
[TBL] [Abstract][Full Text] [Related]
10. PAMAM-modified citric acid-coated magnetic nanoparticles as pH sensitive biocompatible carrier against human breast cancer cells.
Nosrati H; Adibtabar M; Sharafi A; Danafar H; Hamidreza Kheiri M
Drug Dev Ind Pharm; 2018 Aug; 44(8):1377-1384. PubMed ID: 29560737
[TBL] [Abstract][Full Text] [Related]
11. Effects of the surface charge of polyamidoamine dendrimers on cellular exocytosis and the exocytosis mechanism in multidrug-resistant breast cancer cells.
Zhang J; Li M; Wang M; Xu H; Wang Z; Li Y; Ding B; Gao J
J Nanobiotechnology; 2021 May; 19(1):135. PubMed ID: 33980270
[TBL] [Abstract][Full Text] [Related]
12. Pluronic-attached polyamidoamine dendrimer conjugates overcome drug resistance in breast cancer.
Wang M; Li Y; HuangFu M; Xiao Y; Zhang T; Han M; Xu D; Li F; Ling D; Jin Y; Gao J
Nanomedicine (Lond); 2016 Nov; 11(22):2917-2934. PubMed ID: 27780403
[TBL] [Abstract][Full Text] [Related]
13. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
[TBL] [Abstract][Full Text] [Related]
14. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
[TBL] [Abstract][Full Text] [Related]
15. Highly lipophilic pluronics-conjugated polyamidoamine dendrimer nanocarriers as potential delivery system for hydrophobic drugs.
Nguyen TTC; Nguyen CK; Nguyen TH; Tran NQ
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 2):992-999. PubMed ID: 27772731
[TBL] [Abstract][Full Text] [Related]
16. Dye-cored polylysine dendrimer as luminescent nanoplatform for imaging-guided anticancer drug delivery.
Zhu P; Younis MR; Ma G; Zhang Q; An R; Wang K; Dong J
Colloids Surf B Biointerfaces; 2023 Feb; 222():113130. PubMed ID: 36623376
[TBL] [Abstract][Full Text] [Related]
17. Sugar Modification Enhances Cytotoxic Activity of PAMAM-Doxorubicin Conjugate in Glucose-Deprived MCF-7 Cells - Possible Role of GLUT1 Transporter.
Sztandera K; Działak P; Marcinkowska M; Stańczyk M; Gorzkiewicz M; Janaszewska A; Klajnert-Maculewicz B
Pharm Res; 2019 Jul; 36(10):140. PubMed ID: 31367876
[TBL] [Abstract][Full Text] [Related]
18. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.
Gu Z; Wang M; Fang Q; Zheng H; Wu F; Lin D; Xu Y; Jin Y
Drug Dev Ind Pharm; 2015 May; 41(5):812-8. PubMed ID: 24745851
[TBL] [Abstract][Full Text] [Related]
19. Impact of dendrimer surface functional groups on the release of doxorubicin from dendrimer carriers.
Zhang M; Guo R; Kéri M; Bányai I; Zheng Y; Cao M; Cao X; Shi X
J Phys Chem B; 2014 Feb; 118(6):1696-706. PubMed ID: 24467521
[TBL] [Abstract][Full Text] [Related]
20. Targeted and pH-responsive delivery of doxorubicin to cancer cells using multifunctional dendrimer-modified multi-walled carbon nanotubes.
Wen S; Liu H; Cai H; Shen M; Shi X
Adv Healthc Mater; 2013 Sep; 2(9):1267-76. PubMed ID: 23447549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
